DELIVERY ORDER
Active75A50126F61002
Department of Health and Human Services › Office of Assistant Secretary for Preparedness and Response › BARDA - ASPR / DAAPPO / BARDA DCMA
$3.7M
obligated · signed 1 month ago
RTOR BIO-AMT-2312: ASSESSMENT OF THE THERAPEUTIC POTENTIAL OF CHLOROQUINE AND OSELTAMIVIR IN TWO (2) LETHAL MODELS OF INFLUENZA A H5N1
Performance timeline
Start
Aug 26, 2026
End
Apr 25, 2028
with all options
Loading status
Estimated start: Apr 25, 2027
LOVELACE BIOMEDICAL RESEARCH INSTITUTE
Contract 75A50126F61002
UEI
MBT9RXJJ7428
Parent Company
LOVELACE BIOMEDICAL RESEARCH INSTITUTE
Capabilities & Certifications
Headquarters Location
Congressional District: 01
Current Obligation
$3,723,027
Base + Exercised Options
$3,723,027
Total Ceiling Value
$3,723,027
Contract Type
COST PLUS FIXED FEE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
Place of Performance
Congressional District: 01
Awarding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Funding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Contract Vehicle
75A50122D00021
IDCDepartment of Health and Human Services
Award type: SINGLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.